

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

**Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **June 8, 2012**

BIOSANTE PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-31812
(Commission File Number)

58-2301143
(I.R.S. Employer
Identification Number)

111 Barclay Boulevard
Lincolnshire, Illinois
(Address of principal executive offices)

60069
(Zip Code)

Registrant's telephone number, including area code: **(847) 478-0500**

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

As previously announced, on June 1, 2012, BioSante Pharmaceuticals, Inc. ("BioSante") effected a one-for-six reverse split of its issued and outstanding common stock and class C special stock.

BioSante is filing this current report on Form 8-K to present selected financial data for the fiscal years ended December 31, 2011, 2010, 2009, 2008 and 2007 and for the quarterly periods ended March 31, 2012 and 2011, as adjusted to reflect the June 1, 2012 one-for-six reverse stock split.

The information contained in Exhibit 99.1 to this report is incorporated by reference in this Item 8.01 and should be read in conjunction with, and as a supplement to, information contained in BioSante's annual report on Form 10-K for its fiscal year ended December 31, 2011, quarterly report on Form 10-Q for the quarterly period ended March 31, 2012 and any other reports or filings made by BioSante with the Securities and Exchange Commission.

Item 9.01 Financial Statements and Exhibits.

(d) *Exhibits.*

<u>Exhibit No.</u>	<u>Description</u>
99.1	Selected Financial Data of BioSante for the fiscal years ended December 31, 2011, 2010, 2009, 2008 and 2007 and for the quarterly periods ended March 31, 2012 and 2011, as adjusted to reflect the one-for-six reverse split of BioSante's issued and outstanding common stock and class C special stock on June 1, 2012 (filed herewith)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOSANTE PHARMACEUTICALS, INC.

By: /s/ Phillip B. Donenberg
Phillip B. Donenberg
*Senior Vice President of Finance,
Chief Financial Officer and Secretary*

Dated: June 8, 2012

3

BIOSANTE PHARMACEUTICALS, INC.

FORM 8-K

Exhibit Index

<u>Exhibit No.</u>	<u>Description</u>	<u>Method of Filing</u>
99.1	Selected Financial Data of BioSante for the fiscal years ended December 31, 2011, 2010, 2009, 2008 and 2007 and for the quarterly periods ended March 31, 2012 and 2011, as adjusted to reflect the one-for-six reverse split of BioSante's issued and outstanding common stock and class C special stock on June 1, 2012	Filed herewith

4

BIOSANTE PHARMACEUTICALS, INC.
SELECTED FINANCIAL DATA

	Year Ended December 31,					Three Months Ended March 31,	
	2011	2010	2009	2008	2007	2012	2011
	(in thousands, except per share data)						
Statement of Operations Data:							
Revenue	\$ 435	\$ 2,474	\$ 1,258	\$ 3,781	\$ 493	\$ 114	\$ 57
Expenses							
Research and development	44,182	39,706	13,681	15,790	4,751	5,183	14,864
General and administration	6,982	5,940	5,374	5,125	4,331	1,832	1,594
Acquired in-process research and development	—	—	9,000	—	—	—	—
Excess consideration paid over fair value	—	—	20,192	—	—	—	—
Licensing expense	50	269	300	836	—	—	—
Depreciation and amortization	148	168	137	43	90	31	42
Total expenses	51,362	46,083	48,684	21,794	9,172	7,046	16,500
Other (expense) income — Convertible note fair value adjustment	(23)	(1,871)	33	—	—	(3,210)	(639)
Other expense — Investment impairment charge	—	(286)	—	—	—	—	—
Other interest (expense) income	(673)	(675)	(135)	588	1,095	(124)	(172)
Other income	15	245	—	—	—	2	3
Net loss	\$ (51,608)	\$ (46,196)	\$ (47,528)	\$ (17,425)	\$ (7,584)	\$ (10,264)	\$ (17,251)
Basic and diluted net loss per common share*	\$ (3.15)	\$ (4.21)	\$ (8.40)	\$ (3.83)	\$ (1.79)	\$ (0.53)	\$ (1.22)
Weighted average number of common shares and common equivalent shares outstanding*	16,398	10,985	5,659	4,551	4,248	19,378	14,127

	As of December 31,					As of March 31,	
	2011	2010	2009	2008	2007	2012	2011
	(in thousands)						
Balance Sheet Data:							
Cash, cash equivalents and short-term investments	\$ 57,225	\$ 38,155	\$ 29,858	\$ 14,787	\$ 30,655	\$ 49,474	\$ 51,349
Total assets	62,380	44,767	36,437	17,679	31,241	54,575	56,805
Total current liabilities (includes short-term convertible senior notes in 2010)	7,228	8,183	3,930	3,853	1,516	6,085	12,633
Convertible senior notes, total long-term	17,337	17,436	16,676	—	—	10,494	18,037
Stockholders' equity	37,815	19,147	15,830	13,826	29,725	37,996	26,136

* All share and per share numbers have been adjusted retroactively to reflect the one-for-six reverse stock split effected on June 1, 2012.